Neogen Reports Mixed Fiscal Year 2026 Results Amid Strategic Shifts — Neogen Corporation

Event summary

Neogen reported fiscal year 2026 revenue of $870.4 million, down 2.7% from the previous year.
Food Safety segment revenue grew 3.1% in Q4, while Animal Safety segment revenue declined 8.2%.
The company expects to complete the sale of its Genomics business to Zoetis Inc. by the end of the first half of fiscal year 2027 for $160 million.
Neogen provided fiscal year 2027 guidance, targeting revenue between $880 million and $885 million.

The big picture

Neogen's fiscal year 2026 results reflect ongoing challenges in the Animal Safety segment, offset by growth in Food Safety solutions. The planned divestiture of its Genomics business to Zoetis Inc. marks a strategic pivot aimed at debt reduction and operational streamlining. As Neogen navigates regulatory hurdles and market dynamics, its ability to execute on new commercial initiatives will be key to sustaining profitability and growth.

What we're watching

Execution Risk: The pace at which Neogen can integrate its new global go-to-market strategy and enterprise-wide solutions-based selling model will be critical to meeting fiscal year 2027 revenue targets.
Regulatory Headwinds: The progress of the ACCC and NZCC reviews for Neogen’s proposed genomics divestiture could impact the timing and completion of the transaction with Zoetis Inc.
Market Dynamics: How Neogen’s focus on high-impact innovation and operational efficiency through additive technology will position it in a competitive food safety market.